摘要
Objective Astragaloside Ⅳ derivative(ASId) is one of Astragaloside Ⅳ(ASI) derivatives with higher water-solubility and may have more druggability than ASI.The present study aims at observing the effects of ASId on cardiovascular parameters in chronic heart failure in rats.Methods Using echocardiographic and haemodynamic measurements,the effects of ASId on congestive heart failure(CHF) induced by ligation of the left coronary artery in rats were investigated.Results ASId iv 0.5,1.0,and 2.0 mg/(kg·d) attenuated the decline of ejection fraction.The peak derivatives of the left ventricle(LV) pressure(dp/dt) in ASId treated groups were significantly increased.Both LV volumes in diastole and in systole were decreased significantly after ASId treatment,accompanied with a trend towards normalization of relative wall thickness at end-systole.ASId 0.5,1.0,and 2.0 mg/(kg·d) attenuated the increase of LV systolic and diastolic wall stress.ASId treatment also inhibited compensatory hypertrophy of depressed heart.Conclusion ASId could improve cardiac functions and inhibite compensatory hypertrophy and LV remodelling,which suggests the possibility of ASId as a new therapeutic drug for the treatment of CHF.
Objective Astragaloside Ⅳ derivative(ASId) is one of Astragaloside Ⅳ(ASI) derivatives with higher water-solubility and may have more druggability than ASI.The present study aims at observing the effects of ASId on cardiovascular parameters in chronic heart failure in rats.Methods Using echocardiographic and haemodynamic measurements,the effects of ASId on congestive heart failure(CHF) induced by ligation of the left coronary artery in rats were investigated.Results ASId iv 0.5,1.0,and 2.0 mg/(kg·d) attenuated the decline of ejection fraction.The peak derivatives of the left ventricle(LV) pressure(dp/dt) in ASId treated groups were significantly increased.Both LV volumes in diastole and in systole were decreased significantly after ASId treatment,accompanied with a trend towards normalization of relative wall thickness at end-systole.ASId 0.5,1.0,and 2.0 mg/(kg·d) attenuated the increase of LV systolic and diastolic wall stress.ASId treatment also inhibited compensatory hypertrophy of depressed heart.Conclusion ASId could improve cardiac functions and inhibite compensatory hypertrophy and LV remodelling,which suggests the possibility of ASId as a new therapeutic drug for the treatment of CHF.
作者
WANG Wei-ting1,ZHAO Zhuan-you1,HAN Ying-mei2,XU Wei-ren2,TANG Li-da1 1.State Key Laboratory of Pharmacokinetics and Pharmacodynamics,Tianjin Institute of Pharmaceutical Research,Tianjin 300193,China 2.Tianjin Key Laboratory of Molecular Design & Drug Discovery,Tianjin Institute of Pharmaceutical Research,Tianjin 300193,China
基金
supported by a grant from the National Key Technolody R&D Program (NO.2007BAI41B02)
